(Q33429195)

26 July 2017

title

Myelodysplastic syndromes: Contemporary review and how we treat (English)

1 reference

26 July 2017

3

Ayalew Tefferi

1 reference

26 July 2017

Naseema Gangat

1

1 reference

26 July 2017

Mrinal M Patnaik

series ordinal

2

1 reference

26 July 2017

publication date

1 January 2016

1 reference

American Journal of Hematology

26 July 2017

published in

1 reference

26 July 2017

volume

91

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

76-89

1 reference

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

26 July 2017

cites work

1 reference

The epidemiology of myelodysplastic syndromes

21 January 2018

1 reference

Revised international prognostic scoring system for myelodysplastic syndromes

21 January 2018

1 reference

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

21 January 2018

1 reference

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients

21 January 2018

1 reference

SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value

21 January 2018

1 reference

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

21 January 2018

1 reference

Frequent pathway mutations of splicing machinery in myelodysplasia

21 January 2018

1 reference

Clinical effect of point mutations in myelodysplastic syndromes

21 January 2018

1 reference

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes

21 January 2018

1 reference

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

Clinical and biological implications of driver mutations in myelodysplastic syndromes

21 January 2018

1 reference

Dyskeratosis congenita in all its forms

21 January 2018

1 reference

Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis

21 January 2018

1 reference

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

21 January 2018

1 reference

Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach

21 January 2018

1 reference

Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification.

21 January 2018

1 reference

Clinical and genetic characteristics of congenital sideroblastic anemia: comparison with myelodysplastic syndrome with ring sideroblast (MDS-RS).

21 January 2018

1 reference

Vitamin B(12)-responsive pancytopenia mimicking myelodysplastic syndrome

21 January 2018

1 reference

Severe vitamin B12 deficiency resulting in pancytopenia, splenomegaly and leukoerythroblastosis

21 January 2018

1 reference

Hematological manifestations of copper deficiency: a retrospective review

21 January 2018

1 reference

Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors

21 January 2018

1 reference

Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification

21 January 2018

1 reference

Proposals for the classification of the myelodysplastic syndromes

21 January 2018

1 reference

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

21 January 2018

1 reference

SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes

21 January 2018

1 reference

Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts.

21 January 2018

1 reference

Distinct haematological disorder with deletion of long arm of no. 5 chromosome

21 January 2018

1 reference

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

21 January 2018

1 reference

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.

21 January 2018

1 reference

Multi-color CD34⁺ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia

21 January 2018

1 reference

Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics

21 January 2018

1 reference

MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance

21 January 2018

1 reference

Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS.

21 January 2018

1 reference

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge

21 January 2018

1 reference

A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients

21 January 2018

1 reference

Clinical significance of Y chromosome loss in hematologic disease

21 January 2018

1 reference

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

21 January 2018

1 reference

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype

21 January 2018

1 reference

Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

21 January 2018

1 reference

Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes

21 January 2018

1 reference

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

21 January 2018

1 reference

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation

21 January 2018

1 reference

Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.

21 January 2018

1 reference

Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Reg

21 January 2018

1 reference

Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.

21 January 2018

1 reference

A prognostic score for patients with lower risk myelodysplastic syndrome

21 January 2018

1 reference

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

21 January 2018

1 reference

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

21 January 2018

1 reference

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation

21 January 2018

1 reference

Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.

21 January 2018

1 reference

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

21 January 2018

1 reference

A review of 76 patients with myelodysplastic syndromes treated with danazol

21 January 2018

1 reference

Current concepts in the pathophysiology and treatment of aplastic anemia

21 January 2018

1 reference

Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy.

21 January 2018

1 reference

The clinical relevance of minor paroxysmal nocturnal hemoglobinuria clones in refractory cytopenia of childhood: a prospective study by EWOG-MDS.

21 January 2018

1 reference

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.

21 January 2018

1 reference

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study

21 January 2018

1 reference

Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.

21 January 2018

1 reference

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia

21 January 2018

1 reference

Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

21 January 2018

1 reference

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes

21 January 2018

1 reference

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

21 January 2018

1 reference

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

21 January 2018

1 reference

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure

21 January 2018

1 reference

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome

21 January 2018

1 reference

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis

21 January 2018

1 reference

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.24253

1 reference

26 July 2017

1 reference